Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 09, 2023, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 09, 2023, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.".